Drug Report History #156638
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v42-EN | Version v15-EN | |
|---|---|---|
| Language | English | English |
| Date Updated (Changed) | Updated to: 2022-12-28 | Was: 2022-07-30 |
| Drug Identification Number | 02243278 | 02243278 |
| Brand name | LORAZEPAM INJECTION USP | LORAZEPAM INJECTION USP |
| Common or Proper name | LORAZEPAM | LORAZEPAM |
| Company Name | SANDOZ CANADA INCORPORATED | SANDOZ CANADA INCORPORATED |
| Ingredients | LORAZEPAM | LORAZEPAM |
| Strength(s) | 4MG | 4MG |
| Dosage form(s) | SOLUTION LIQUID | SOLUTION LIQUID |
| Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 1ML 10LIVI | 1ML 10LIVI |
| Additional packaging sizes | ||
| ATC code | N05BA | N05BA |
| ATC description | ANXIOLYTICS | ANXIOLYTICS |
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date (Changed) | Updated to: 2022-09-19 | Was: |
| Actual start date (Changed) | Updated to: 2022-09-19 | Was: 2022-07-29 |
| Estimated end date (Changed) | Updated to: 2022-12-23 | Was: 2022-09-02 |
| Actual end date (Changed) | Updated to: 2022-12-21 | Was: |
| Shortage status (Changed) | Updated to: Resolved | Was: Actual shortage |
| Tier 3 Status (Changed) | Updated to: Yes | Was: No |
| Company comments (Changed) | Updated to: Inventory is available at Wholesalers on Allocation (100% of Historical demand). Allocation to remain in place until June 2023. | Was: |
| Health Canada comments |